Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

We Should Revascularize Patients with Stable Coronary Syndromes and Ischemia Assessed by iFR

Chronic stable angina has shown a good response to medical treatment, and the Ischemia study has recently demonstrated the safety of such treatment in stable chronic angina with moderate to severe ischemia. However, this study excluded left main coronary artery (LMCA) lesions.

Debemos revascularizar los pacientes con síndromes coronarios estables e isquemia evaluada mediante iFR 

The FAME Study has shown the safety and efficacy of fractional flow reserve (FFR), as well as a reduction in the need for stent. However, in stable syndromes with ischemia assessed based on left main coronary artery physiology, it has not been analyzed whether current medical treatment is safe.

Researchers conducted a review of the DEFINE LM registry, which included 225 patients with stable chronic angina and significant lesions for ischemia, determined by instantaneous wave-free ratio (iFR) ≤0.89. Of these, 74 patients were deferred for medical treatment, while 151 patients underwent revascularization.

The Primary Endpoint (PEP) was defined as major adverse cardiovascular events (MACE), which includes mortality from any cause, non-fatal acute myocardial infarction, and revascularization of the LMCA lesion due to ischemia.

Since the populations were different, researchers conducted a propensity score match analysis, which resulted in 74 patients in each group.

The mean age of the participants was 71 years; 52% of patients were men and 80% had hypertension. Additionally, 42% had diabetes, 24% had chronic renal insufficiency, and 30% had experienced a previous myocardial infarction.

Read also: VASC-OBSERVANT II Substudy: Impact of Vascular Complications after TAVR.

The most common lesion in the left main coronary artery was distal (80%), followed by ostium lesions, while the lesion in the body of the LMCA was less frequent. There were no differences in the number of diseased vessels or in the presence of chronic total occlusion (CTO).

The SYNTAX Score was 22.

In the group of patients who underwent revascularization, percutaneous coronaryintervention (PCI) was performed in 44 cases, and myocardial revascularization surgery (MRS) was performed in 30 cases.

Read also: Calcified Nodules and the Importance of OCT Categorization prior PCI.

Follow-up was conducted over 34 months (22-40). Regarding the PEP, there was a benefit in favor of revascularization was, with an incidence of 14.9% versus 28.4% (hazard ratio 0.42 [95% confidence interval (CI), 0.20-0.89]; p=0.023). Furthermore, there was a reduction in cardiac mortality and LMCA-related myocardial infarction (0% vs. 8.1%; p=0.004), as well as in the need for revascularization of LMCA lesions (5.4% vs. 17.6%; hazard ratio, 0.20 [95% CI, 0.056-0.70]; p=0.012).

The predictor of MACE reduction was LMCA revascularization.

Conclusion

In summary, patients who underwent revascularization for stable coronary disease and significant lesions identified by iFR physiology had a more favorable long-term outcome compared to those whose revascularization was deferred.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Deferred Versus Performed Revascularization for Left Main Coronary Disease With Hemodynamic Significance.

Reference: Warisaw, et al. Circ Cardiovasc Interv. 2023;16:e012700. DOI: 10.1161/CIRCINTERVENTIONS.122.012700.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

DOUBLE-CHOICE: Lower Pacemaker Implantation Rates with ACURATE neo2 Compared with Evolut in Patients Undergoing TAVI

The DOUBLE-CHOICE trial is a multicenter, randomized, controlled study conducted in Germany to evaluate the performance of next-generation transcatheter heart valves and different anesthesia...

GLUCO-TAVI | Can Glucocorticoids Reduce the Need for Permanent Pacemaker Implantation After TAVI?

Despite the expansion of transcatheter aortic valve implantation (TAVI) indications, cardiac conduction disturbances (CCD) and the need for permanent pacemaker implantation (PPI) remain the...

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....